284 related articles for article (PubMed ID: 29278971)
21. Statistical issues in trials of preexposure prophylaxis.
Dunn DT; Glidden DV
Curr Opin HIV AIDS; 2016 Jan; 11(1):116-21. PubMed ID: 26545264
[TBL] [Abstract][Full Text] [Related]
22. What does preexposure prophylaxis mean for treatment; what does treatment mean for preexposure prophylaxis?
Venter WD
Curr Opin HIV AIDS; 2016 Jan; 11(1):35-40. PubMed ID: 26545265
[TBL] [Abstract][Full Text] [Related]
23. Better late than never: PrEP in England.
The Lancet Hiv
Lancet HIV; 2017 Jan; 4(1):e1. PubMed ID: 28007341
[No Abstract] [Full Text] [Related]
24. The Danish PEP Registry: Experience with the use of post-exposure prophylaxis following blood exposure to HIV from 1999-2012.
Lunding S; Katzenstein TL; Kronborg G; Storgaard M; Pedersen C; Mørn B; Lindberg JÅ; Kronborg TM; Jensen J
Infect Dis (Lond); 2016; 48(3):195-200. PubMed ID: 26529586
[TBL] [Abstract][Full Text] [Related]
25. Laboratory Testing of a Cohort of Commercially Insured Users of HIV Preexposure Prophylaxis in the United States, 2011-2015.
Huang YA; Tao G; Samandari T; Hoover KW
J Infect Dis; 2018 Jan; 217(4):617-621. PubMed ID: 29145597
[TBL] [Abstract][Full Text] [Related]
26. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
Parikh UM; Mellors JW
Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640
[TBL] [Abstract][Full Text] [Related]
27. Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches.
Brown JL; Sales JM; DiClemente RJ
Curr HIV/AIDS Rep; 2014 Dec; 11(4):363-75. PubMed ID: 25216985
[TBL] [Abstract][Full Text] [Related]
28. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice.
Haberer JE
Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638
[TBL] [Abstract][Full Text] [Related]
29. Pediatric Considerations for Postexposure Human Immunodeficiency Virus Prophylaxis.
Muller WJ; Chadwick EG
Infect Dis Clin North Am; 2018 Mar; 32(1):91-101. PubMed ID: 29406979
[TBL] [Abstract][Full Text] [Related]
30. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Özdener AE; Park TE; Kalabalik J; Gupta R
Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
[TBL] [Abstract][Full Text] [Related]
31. [HIV post exposure prophylaxis therapy - the experience of two major AIDS centers].
Elbirt D; Levy I; Asher I; Mahlev-Guri K; Rosenberg-Bezalet S; Litachevsky S; Radian-Sade S; Sthoeger Z
Harefuah; 2013 Apr; 152(4):224-9, 246. PubMed ID: 23844525
[TBL] [Abstract][Full Text] [Related]
32. Combining biomedical preventions for HIV: Vaccines with pre-exposure prophylaxis, microbicides or other HIV preventions.
McNicholl JM
Hum Vaccin Immunother; 2016 Dec; 12(12):3202-3211. PubMed ID: 27679928
[TBL] [Abstract][Full Text] [Related]
33. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.
Kuhar DT; Henderson DK; Struble KA; Heneine W; Thomas V; Cheever LW; Gomaa A; Panlilio AL;
Infect Control Hosp Epidemiol; 2013 Sep; 34(9):875-92. PubMed ID: 23917901
[TBL] [Abstract][Full Text] [Related]
34. What Community-Based HIV Prevention Organizations Say About Their Role in Biomedical HIV Prevention.
Smith DK; Maier E; Betts J; Gray S; Kolodziejski B; Hoover KW
AIDS Educ Prev; 2016 Oct; 28(5):426-439. PubMed ID: 27710082
[TBL] [Abstract][Full Text] [Related]
35. Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.
Smith DK; Van Handel M; Wolitski RJ; Stryker JE; Hall HI; Prejean J; Koenig LJ; Valleroy LA
MMWR Morb Mortal Wkly Rep; 2015 Nov; 64(46):1291-5. PubMed ID: 26606148
[TBL] [Abstract][Full Text] [Related]
36. Impact of pre-exposure and post-exposure prophylaxes prevention programme on HIV burden and services in a low-resource setting: a simulation modelling approach.
Adeoti AO; Demir E; Adeyemi S; Yakutcan U; Kengne AP; Kayode G; Aliyu A; Idika N; Isichei C
Pan Afr Med J; 2021; 40():163. PubMed ID: 34970405
[TBL] [Abstract][Full Text] [Related]
37. Ethical use of antiretroviral resources for HIV prevention in resource poor settings.
Rennie S
Dev World Bioeth; 2013 Aug; 13(2):79-86. PubMed ID: 23724978
[TBL] [Abstract][Full Text] [Related]
38. Prescription of Postexposure Prophylaxis for HIV-1 in the Emergency Room: Correct Transmission Risk Assessment Remains Challenging.
Marzel A; Heinrich H; Schilliger L; Fehr JS; Günthard HF; Kouyos R; Rampini SK
J Acquir Immune Defic Syndr; 2017 Apr; 74(4):359-366. PubMed ID: 27906766
[TBL] [Abstract][Full Text] [Related]
39. New Canadian guideline provides evidence-based approach to non-occupational HIV prophylaxis.
O'Donnell S; Tan DHS; Hull MW
CJEM; 2019 Jan; 21(1):21-25. PubMed ID: 30457087
[TBL] [Abstract][Full Text] [Related]
40. HIV exposure through contact with body fluids.
Prescrire Int; 2012 Apr; 21(126):100-1, 103-5. PubMed ID: 22515138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
